Post-translational modification derived products (PTMDPs): Toxins in chronic diseases?

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 1, 2014, Pages 33-38

  Gillery, Philippe ^a,b   Jaisson, Stéphane ^a,b  

^a AMERICAN MEMORIAL HOSPITAL   (France)

^b UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

Author keywords

carbamylation; chronic renal failure; diabetes mellitus; glycation; non enzymatic post translational modifications; uremic toxins

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINO ACID; CARBOHYDRATE DERIVATIVE; GELATINASE B; HOMOCITRULLINE; ISOCYANATE; LIPOPROTEIN; LYSINE; MEMBRANE RECEPTOR; MYELOPEROXIDASE; POSTTRANSLATIONAL MODIFICATION DERIVED PRODUCT; SCLEROPROTEIN; THIOCYANATE; TOXIN; UNCLASSIFIED DRUG; UREA;

ATHEROGENESIS; BINDING AFFINITY; CARBAMOYLATION; CELL INTERACTION; CHRONIC DISEASE; CHRONIC KIDNEY FAILURE; DIABETES MELLITUS; DISSOCIATION; GLYCATION; GLYCOXIDATION; HYPERGLYCEMIA; INTRACELLULAR SIGNALING; NEUTROPHIL; OXIDATION; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN MODIFICATION; REVIEW;

CARBAMATES; DIABETES MELLITUS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEINS; TOXINS, BIOLOGICAL;

EID: 84891432758     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0880     Document Type: Review

References (40)

1. Jaisson S, Gillery P. Evaluation of nonenzymatic posttranslational modification-derived products as biomarkers of molecular aging of proteins. Clin Chem 2010;56:1401-12.
2. Jaisson S, Pietrement C, Gillery P. Carbamylation derived products (CDPs): bioactive compounds and potential biomarkers in chronic renal failure and atherosclerosis. Clin Chem 2011;57:1499-505.
3. D'Agati V, Schmidt AM. RAGE and the pathogenesis of chronic kidney disease. Nature Rev Nephrol 2010;6:352-60.
4. Ahmed N, Thornalley PJ. Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes Obes Metab 2007;9:233-45.
5. Gillery P. A history of HbA1c through Clinical Chemistry and Laboratory Medicine. Clin Chem Lab Med 2013;51:65-74.
6. Mosca A, Lapolla A, Gillery P. Glycemic control in the clinical management of diabetic patients. Clin Chem Lab Med 2013;51:753-66.
7. Baynes JW, Thorpe SR. Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 2000;28;1708-16.
8. Baynes JW. Chemical modification of proteins by lipids in diabetes. Clin Chem Lab Med 2003;41:1159-65.
9. Witko-Sarsat V, Nguyen-Khoa T, Jungers P, Drueke TB, Descamps-Latscha B. Advanced oxidation protein products as a novel molecular basis of oxidative stress in uraemia. Nephrol Dial Transplant 1999;14(Suppl 1):76-8.
10. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006;114:597-605.
11. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 2008;196:9-21.
12. Takeuchi M, Yamagishi S. Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease. J Alzheimers Dis 2009;16:845-58.
13. Vlassara H, Striker G. Glycotoxins in the diet promote diabetes and diabetic complications. Curr Diab Rep 2007;7:235-41.
14. Gillery P, Monboisse JC, Maquart FX, Borel JP. Glycation of proteins as a source of superoxide. Diab Metab 1988;14: 25-30.
15. Bailey AJ, Paul RG, Knott L. Mechanisms of maturation and ageing of collagen. Mech Ageing Dev 1998;106:1-56.
16. Monboisse JC, Rittié L, Lamfarraj H, Garnotel R, Gillery P. In vitro glycoxidation alters the interactions between collagens and human polymorphonuclear leucocytes. Biochem J 2000;350:777-83.
17. Touré F, Zahm JM, Garnotel R, Lambert E, Bonnet N, Schmidt AM, et al. Receptor for advanced glycation end products (RAGE) modulates neutrophil adhesion and migration on glycoxidated extracellular matrix. Biochem J 2008;416:255-61.
18. Thornalley PJ. Advanced glycation end products in renal failure. J Ren Nutr 2006;16:178-84.
19. Stark GR, Stein WH, Moore S. Reactions of the cyanate present in aqueous urea with aminoacids and proteins. J Biol Chem 1960;235:3177-81.
20. Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Hörkkö S, Barnard J, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007;13:1167-84.
21. Roberts JM, Veres PR, Cochran AK, Warneke C, Burling IR, Yokelson RJ, et al. Isocyanic acid in the atmosphere and its possible link to smoke related health effects. Proc Natl Acad Sci USA 2011;108:8966-71.
22. Kraus LM, Kraus AP Jr. Carbamoylation of amino acids and proteins in uremia. Kidney Int Suppl 2001;78:S102-7.
23. Kraus LM, Jones MR, Kraus AP Jr. Essential carbamoyl-amino acids formed in vivo in patients with end-stage renal disease managed by continuous ambulatory peritoneal dialysis: isolation, identification, and quantitation. J Lab Clin Med 1998;131:425-31.
24. Kraus LM, Kraus AP Jr. The search for the uremic toxin: the case for carbamoylation of amino acids and proteins. Wien Klin Wochenschr 1998;110:521-30.
25. Schreier SM, Hollaus M, Hermann M, Jirovetz L, Exner M, Kapiotis S, et al. Carbamoylated free amino acids in uremia: HOCl generates volatile protein modifying and cytotoxic oxidant species form N-carbamoyl-threonine but not threonine. Biochimie 2012;94:2441-7.
26. Dengler TJ, Robertz-Vaupel GM, Dengler HJ. Albumin binding in uremia: quantitative assessment of inhibition by endogenous ligands and carbamylation of albumin. Eur J Clin Pharmacol 1992;43:491-9.
27. Jaisson S, Delevallée-Forte C, Touré F, Rieu P, Garnotel R, Gillery P. Carbamylated albumin is a potent inhibitor of polymorphonuclear neutrophil respiratory burst. FEBS Lett 2007;581:1509-13.
28. Gross ML, Piecha G, Bierhaus A, Hanke W, Henle, T, Schirmacher P, et al. Glycated and carbamylated albumin are more "nephrotoxic" than unmodified albumin in the amphibian kidney. Am J Physiol Renal Physiol 2011;301:F476-85.
29. Apostolov EO, Shah SV, Ok E, Basnakian AG. Carbamylated low-density lipoprotein induces monocyte adhesion to endothelial cells through intercellular adhesion molecule-1 and vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol 2007;27:826-32.
30. Asci G, Basci A, Shah SV, Basnakian A, Toz H, Ozkahya M, et al. Carbamylated low-density lipoprotein induces proliferation and increases adhesion molecule expression of human coronary artery smooth muscle cells. Nephrology 2008;13:480-6.
31. Carracedo J, Merino A, Briceno C, Soriano S, Buendia P, Calleros L, et al. Carbamylated low-density lipoprotein induces oxidative stress and accelerated senescence in human endothelial progenitor cells. FASEB J 2011;25:1314-22.
32. Holzer M, Birner-Gruenberger R, Stojakovic T, El-Gamal D, Binder V, Wadsack C, et al. Uremia alters HDL composition and function. J Am Soc Nephrol 2011;22:1631-41.
33. Holzer M, Zangger K, El-Gamal D, Binder V, Curcic S, Konya V, et al. Myeloperoxidase-derived chlorinating species induce protein carbamylation through decomposition of thiocyanate and urea: novel pathways generating dysfunctional high-density lipoprotein. Antioxid Redox Signal 2012;8:1043-52.
34. Nigen AM, Njikam N, Lee CK, Manning JM. Studies on the mechanism of action of cyanate in sickle cell disease. Oxygen affinity and gelling properties of hemoglobin S carbamylated on specific chains. J Biol Chem 1974;249:6611-6.
35. Harding JJ. Viewing molecular mechanisms of ageing through a lens. Ageing Res Rev 2002;1:465-79.
36. Jaisson S, Lorimier S, Ricard-Blum S, Sockalingum GD, Delevallée-Forte C, Kegelaer G, et al. Impact of carbamylation on type I collagen conformational structure and its ability to activate human polymorphonuclear neutrophils. Chem Biol 2006;13:149-59.
37. Jaisson S, Larreta-Garde V, Bellon G, Hornebeck W, Garnotel R, Gillery P. Carbamylation differentially alters type I collagen sensitivity to various collagenases. Matrix Biol 2007;26: 190-6.
38. Garnotel R, Sabbah N, Jaisson S, Gillery P. Enhanced activation of and increased production of matrix metalloproteinase-9 by human blood monocytes upon adhering to carbamylated collagen. FEBS Lett 2004;563:13-6
39. Shaykh M, Pegoraro AA, Mo W, Arruda JA, Dunea G, Singh AK. Carbamylated proteins activate glomerular mesangial cells and stimulate collagen deposition. J Lab Clin Med 1999;133:302-8.
40. Kraus LM, Gaber L, Handorf CR, Marti HP, Kraus AP Jr. Carbamoylation of glomerular and tubular proteins in patients with kidney failure: A potential mechanism of ongoing renal damage. Swiss Med Wkly 2001;131:139-45.